KMT2A and monoclonal gammopathy: Last, interrogating the MLL Munich Leukemia Laboratory WGS dataset of 4,995 patients with various myeloid and lymphoid neoplasms (including 20 patients with monoclonal gammopathy of undetermined significance and 399 MM patients with anti-BCMA therapy-naive patients), 33 patients (0.7%, including 3 MM patients) demonstrated germline variants or variants of unknown significance in TNFRSF17. The list of identified mutations is given in Supplementary Table 4.